← Leaderboards
William W Bachovchin
Tufts University Boston
$4,624,316
Attributed
$5,684,205
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2011–16$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$5,684,205 · 7
By mechanism
R01$2,964,427 · 2
R42$1,066,916 · 1
R41$1,052,862 · 3
S10$600,000 · 1
Top collaborators
- Barry Jones7 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorKillingsToxic EffectIn VivoResistanceBaseMalignant NeoplasmsTumor AntigensTumor GrowthAccountingCessation Of LifeInhibitor/AntagonistMouse ModelResponseFamilyCytotoxicFibroblast-Activating FactorCleaved CellCytotoxic AgentFibroblastsAntineoplastic AgentsEnzymesBreastEpithelial
Grant awards (18)
UPGRADE AND CRYOGENIC PROBE FOR A 600 MHZ NMR SYSTEM FOR BIOMEDICAL RESEARCH$600,000
S10 · FY2016 · OD · contact PI
Using FAP to Selectively Target Epithelial Cancers$349,435
R01 · FY2016 · CA · contact PI
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors$532,072
R42 · FY2015 · CA
Using FAP to Selectively Target Epithelial Cancers$349,435
R01 · FY2015 · CA · contact PI
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors$534,844
R42 · FY2014 · CA
Using FAP to Selectively Target Epithelial Cancers$325,084
R01 · FY2014 · CA · contact PI
A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma$160,721
R41 · FY2014 · CA
Using FAP to Selectively Target Epithelial Cancers$334,999
R01 · FY2013 · CA · contact PI
A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma$232,852
R41 · FY2013 · CA
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors$147,010
R41 · FY2013 · CA
Using FAP to Selectively Target Epithelial Cancers$372,632
R01 · FY2012 · CA · contact PI
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors$266,641
R41 · FY2012 · CA
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors$245,638
R41 · FY2011 · CA
STRUCTURE &FUNCTION OF THE SV40 T-AG DNA BINDING DOMAIN$293,225
R01 · FY2004 · GM
STRUCTURE &FUNCTION OF THE SV40 T-AG DNA BINDING DOMAIN$293,225
R01 · FY2003 · GM
STRUCTURE &FUNCTION OF THE SV40 T-AG DNA BINDING DOMAIN$40,010
R01 · FY2003 · GM
STRUCTURE &FUNCTION OF THE SV40 T-AG DNA BINDING DOMAIN$293,225
R01 · FY2002 · GM
STRUCTURE &FUNCTION OF THE SV40 T-AG DNA BINDING DOMAIN$313,157
R01 · FY2001 · GM